Home » Covidien Submits Label Change for Optimark Contrast Agent
Covidien Submits Label Change for Optimark Contrast Agent
Covidien Plc stated that it will voluntarily contraindicate the use of its
Optimark gadoversetamide injection, a gadolinium-based contrast agent or GBCA, in magnetic resonance imaging or MRI procedures involving patients with
severe renal impairment.
RTTNews
RTTNews
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May